| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
YKL-06-062 targets salt-inducible kinases (SIKs), specifically SIK1, SIK2, and SIK3. It is a second-generation inhibitor that exhibits high potency for these kinases. SIKs are involved in the regulation of various cellular processes including metabolism, inflammation, and transcription.
|
|---|---|
| ln Vitro |
YKL 06-062 (0.0004-16 μM; 3 hours) dose-dependently enhances the expression of MITF mRNA [1].
YKL-06-062 is a potent inhibitor of SIK1, SIK2, and SIK3 with IC50 values of 2.12 nM, 1.40 nM, and 2.86 nM, respectively. At concentrations of 0.0004-16 µM for 3 hours, YKL-06-062 dose-dependently increases MITF mRNA expression. The compound is used in research to study SIK biology. |
| ln Vivo |
Specific in vivo activity data for YKL-06-062 are not extensively reported in the available literature. As a potent SIK inhibitor, it is expected to exhibit efficacy in preclinical models of diseases where SIKs play a role. Further research is needed to characterize its pharmacokinetic and pharmacodynamic profiles in animal models.
|
| Enzyme Assay |
The in vitro enzyme inhibition assay for YKL-06-062 typically involves measuring the kinase activity of recombinant SIK1, SIK2, and SIK3 using a standard kinase assay. The compound is incubated with the enzyme, a peptide substrate, and ATP, and the phosphorylation level is quantified to determine the IC50 value.
|
| Cell Assay |
RT-PCR[1]
Cell Types: human melanocytes, UACC62 melanoma cells Tested Concentrations: 0.0004 μM, 0.004 μM, 0.04 μM, 0.4 μM, 4 μM, 8 μM, 16 μM Incubation Duration: 3 hrs (hours) Experimental Results: MITF mRNA expression is not regulated. The in vitro cellular assay for YKL-06-062 typically involves culturing cells that express SIKs in appropriate growth media. Cells are treated with varying concentrations of the compound, and downstream signaling pathways or cellular responses are measured. For example, MITF mRNA expression can be measured using qPCR to assess the compound's effects. |
| Animal Protocol |
In vivo animal studies for YKL-06-062 would typically involve the use of mouse models of metabolic disorders, inflammation, or other diseases where SIKs play a role. Animals would be administered the compound via appropriate routes (e.g., oral gavage or intraperitoneal injection) at various dose levels. Parameters such as metabolic markers, inflammatory markers, and histopathology would be assessed.
|
| ADME/Pharmacokinetics |
YKL-06-062 has a molecular weight of 525.69 g/mol and a molecular formula of C31H39N7O. The IUPAC name is 1-cyclohexyl-3-(2,6-dimethylphenyl)-7-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-1H,2H,3H,4H-pyrimido[4,5-d][1,3]diazin-2-one. The compound has a purity of ≥98%. Further detailed physicochemical properties are available from the manufacturer's data sheets.
|
| Toxicity/Toxicokinetics |
Specific toxicology data for YKL-06-062 are not available in the public domain. The compound is intended for research use only and should be handled with appropriate laboratory safety precautions. Standard safety assessments would be required before any clinical application. Researchers should consult the safety data sheet for detailed handling and disposal information.
|
| References | |
| Additional Infomation |
YKL-06-062 is a second-generation salt-inducible kinase (SIK) inhibitor that targets SIK1, SIK2, and SIK3. It exhibits IC50 values of 2.12 nM for SIK1, 1.40 nM for SIK2, and 2.86 nM for SIK3. The compound is the structural analog of YKL-06-061. It has not yet entered clinical trials and is strictly for preclinical research purposes.
|
| Molecular Formula |
C31H39N7O
|
|---|---|
| Molecular Weight |
525.68766617775
|
| Exact Mass |
525.321
|
| CAS # |
2172617-16-0
|
| PubChem CID |
139600310
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
5.4
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
39
|
| Complexity |
795
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C1N(C2C(C)=CC=CC=2C)CC2=CN=C(NC3C=CC(=CC=3)N3CCN(C)CC3)N=C2N1C1CCCCC1
|
| InChi Key |
GFXPGVPPWWPDPV-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C31H39N7O/c1-22-8-7-9-23(2)28(22)37-21-24-20-32-30(34-29(24)38(31(37)39)27-10-5-4-6-11-27)33-25-12-14-26(15-13-25)36-18-16-35(3)17-19-36/h7-9,12-15,20,27H,4-6,10-11,16-19,21H2,1-3H3,(H,32,33,34)
|
| Chemical Name |
1-cyclohexyl-3-(2,6-dimethylphenyl)-7-[4-(4-methylpiperazin-1-yl)anilino]-4H-pyrimido[4,5-d]pyrimidin-2-one
|
| Synonyms |
YKL06-062; YKL 06-062; YKL-06-062
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~25 mg/mL (~47.56 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9023 mL | 9.5113 mL | 19.0226 mL | |
| 5 mM | 0.3805 mL | 1.9023 mL | 3.8045 mL | |
| 10 mM | 0.1902 mL | 0.9511 mL | 1.9023 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
